Kamari Pharma Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kamari Pharma Ltd. - overview
Established
2018
Location
Ness Ziona, -, Israel
Primary Industry
Biotechnology
About
Based in Israel, and founded in 2018, Kamari Pharma Ltd. operates as a developer of topical and oral drugs for treating skin diseases. In June 2025, Kamari Pharma Ltd. raised USD 23 million in series A funding co-led by new investor BRM Group and returning investor Pontifax Venture Capital, with participation from other unspecified investors.
The company develops topical and oral medications based on patented small peptides that disrupt an ion channel TRPV3. These medications are designed to treat a variety of dermatological conditions, including keratoderma, Olmsted syndrome, pruritus, atopic dermatitis, ichthyosis, lichen simplex chronicus, and other severe inherited skin problems. The company will use the June 2025 funding for clinical development of KM023.
Current Investors
Guangzhou Biotechnology Investment Fund, BRM Group, Pontifax Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Dermatology, Pharmaceutical Research & Development
Website
www.kamaripharma.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Kamari Pharma Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.